Teva Pharmaceutical Industries (NYSE:TEVA) Stock: Insider Richard Francis Sells 250,000 Shares

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) CEO Richard Francis sold 250,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $42.24, for a total transaction of $10,560,000.00. Following the completion of the sale, the chief executive officer owned 927,529 shares of the company’s stock, valued at $39,178,824.96. This trade represents a 21.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Teva Pharmaceutical Industries Stock Performance

TEVA stock opened at $44.52 on Friday. The firm has a 50 day moving average of $40.16 and a two-hundred day moving average of $35.07. Teva Pharmaceutical Industries Ltd. has a 12 month low of $24.01 and a 12 month high of $44.57. The company has a market capitalization of $51.88 billion, a price-to-earnings ratio of 103.53, a P/E/G ratio of 4.09 and a beta of 0.97. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 1.59.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.14. The business had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. Teva Pharmaceutical Industries’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.78 EPS. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently bought and sold shares of the company. Root Financial Partners LLC bought a new position in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $33,000. Cornerstone Planning Group LLC boosted its position in shares of Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after acquiring an additional 755 shares during the period. Western Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth $43,000. Sunbelt Securities Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth $45,000. Finally, CX Institutional bought a new position in Teva Pharmaceutical Industries during the second quarter worth $54,000. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TEVA has been the subject of several recent analyst reports. Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. TD Cowen raised their price objective on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Barclays boosted their target price on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an “overweight” rating in a report on Thursday, October 15th. JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Finally, UBS Group increased their price target on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday, September 4th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus target price of $48.15.

View Our Latest Stock Analysis on Teva Pharmaceutical Industries

Key Headlines Impacting Teva Pharmaceutical Industries

Investors following TEVA have been watching these headlines:

  • Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and maintained an Overweight rating, pointing to potential upside. HC Wainwright also issued a positive forecast for Teva’s FY2026 earnings, though the report provided no further details. Piper Sandler analyst rating HC Wainwright forecast
  • Positive Sentiment: At its R&D Day, Teva outlined a target of $6–7 billion in innovative-medicines revenue by 2030 and highlighted potential first-in-class pipeline treatments, including for Tourette syndrome, celiac disease and intestinal scarring. These are longer-term opportunities, not guaranteed results. Teva R&D Day announcement
  • Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.56 million, reducing his direct ownership by 21.23%. EVP Richard Daniell also sold shares in two reported transactions—20,003 shares on Nov. 11 and 25,000 on Nov. 9—cutting his reported stake. Insider selling can weigh on sentiment, although it does not by itself establish the executives’ view of Teva’s prospects. CEO SEC filing EVP SEC filing

Teva Pharmaceutical Industries Company Profile

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

See Also

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.